The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
 
Inkeun Park
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Chong Kun Dang Pharmaceutical; IPSEN,; Merck/Pfizer; Ono Pharmaceutical
Research Funding - Boryung Pharmaceuticals (Inst); Chong Kun Dang Pharmaceutical (Inst)
 
Shinkyo Yoon
No Relationships to Disclose
 
Il Hwan Kim
No Relationships to Disclose
 
Kwonoh Park
No Relationships to Disclose
 
Suee Lee
No Relationships to Disclose
 
Bhumsuk Keam
Honoraria - Lilly; Merck; Yuhan
Consulting or Advisory Role - CBS Bioscience; Handok; ImmuneOncia; NeoImmuneTech; Trial Informatics
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Joo-Hwan Park
No Relationships to Disclose
 
Jin Young Kim
No Relationships to Disclose
 
Yoon Ji Choi
No Relationships to Disclose
 
Byeong Seok Sohn
No Relationships to Disclose
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)